Topic: Parkinson's disease
Acorda’s share price took a one-two punch this week, with the FDA extending review of its drug-device treatment for Parkinson’s disease by 3 months.
Kyowa Hakko Kirin has posted a look at proof-of-concept data on adenosine A2A receptor antagonist KW-6356 in early Parkinson’s disease patients.
Acorda's chief technology officer Rick Batycky, Ph.D., is leaving the company next week after four years in the role to head up his own operation.
The partners are contributing preclinical programs to a collaboration that will use 23andMe’s genotypic and phenotypic data to accelerate progress.
Armed with positive phase 2b data, resTORbio is planning pivotal trials next year for a drug to prevent respiratory tract infections in the elderly.
An extended-release form of the GLP-1 drug exenatide slowed neurodegeneration in a rat model of Parkinson’s disease.
A startup from Johns Hopkins launched with $36 million to bring a potentially disease-modifying drug into phase 1 for Parkinson’s disease.
Verge Genomics raised $32 million to bring its AI-generated compounds to the clinic against ALS and Parkinson’s disease in the next three years.
Titan gets the OK to start stage two in a trial of its ropinirole implant for Parkinson’s—but has to postpone because of financial constraints.
Four months after Voyager's chief and founder said he would step down, the neurological disease biotech has found a new leader.